Armistice Capital, LLC Macrogenics Inc Transaction History
Armistice Capital, LLC
- $7.08 Billion
- Q4 2024
A detailed history of Armistice Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 6,276,000 shares of MGNX stock, worth $15.4 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
6,276,000
Previous 6,258,000
0.29%
Holding current value
$15.4 Million
Previous $20.6 Million
0.93%
% of portfolio
0.29%
Previous 0.34%
Shares
12 transactions
Others Institutions Holding MGNX
# of Institutions
131Shares Held
56MCall Options Held
28.3KPut Options Held
197K-
Bellevue Group Ag Kuesnacht, V89.93MShares$24.4 Million0.64% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$13.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.32MShares$10.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.49MShares$8.58 Million0.06% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$7.81 Million0.62% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $151M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...